SciencePharma major plunges over 10% after third trial disappointment in a week
Novartis shares plunged more than 10% on Tuesday after disappointing results from a trial of its del-desiran drug. It was the third trial setback to disappoint investors within a week.
C
CNBC★★☆☆☆2026-09-08 07:51Original
Pharma major plunges over 10% after third trial disappointment in a week
Science